Francis A. Farraye, MD
Professor
Boston University School of Medicine
Dept of Medicine
Gastroenterology

MD, Albert Einstein College of Medicine
MSc, Harvard School of Public Health



Dr. Farraye’s clinical interests are in the care of patients with inflammatory bowel disease and the management of colon polyps and colorectal cancer. He is studying Vitamin D absorption in patients with IBD, the management and diagnosis of dysplasia and cancer in patients with IBD, and predictors of pouchitis after ileal pouch-anal anastomosis (IPAA). In the area of colorectal cancer, he is examining the role of hyperplastic polyps as an alternative pathway in the development of colorectal cancer.

Active Staff Privileges
Boston Medical Center
Medicine



2017 American College of Gastroenterology: Presidential Poster Award
2014 Robert Dawson Evans Award for Quality Improvement and Patient Safety: Committee Member
2013 Institute for Health Care Improvement: Boston University Faculty Development Award: Quality Improvement for Department Chiefs
2013 Boston University School of Medicine: Research Mentor of the Year
2012 Richard Farmer Honorary Lecture: Health Care Maintenance in the IBD Patient
2011 U.S. News and World Report: Top Doctor
2010 Boston Magazine: Best of Boston, Gastroenterology
2010 Boston University School of Management: Boston University Faculty Development Award: Pocket MBA for Physicians
2009 American College of Gastroenterology: William Carey Award
2003 American College of Gastroenterology: Board of Governors Achievement Award
2003 New England Crohn’s and Colitis Foundation of America: Humanitarian of the Year
2002 American College of Gastroenterology: Presidential Poster Award
1999 Harvard Community Health Plan: Key Contribution Award
1998 Harvard Pilgrim Health Care: Ebert Fellowship
1995 Harvard Community Health Plan: Key Contribution Award
1993 Harvard Community Health Plan: Key Contribution Award
1990 Harvard Community Health Plan: Peer Recognition Award
1990 Harvard Community Health Plan: Diamond Award
1990 Harvard Community Health Plan: Key Contribution Award
1986 Harvard Community Health Plan: Peer Recognition Award
1979 American Liver Foundation: Research Fellowship
1979 American Gastroenterological Association: Research Fellowship


A PHASE III, OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB (MLN0002) IN PATIENTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE
04/01/2009 - 09/30/2017 (PI)
Millennium Pharmaceuticals, Inc.

PUCCINI-PROSPECTIVE COHORT OF ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS UNDERGOING SURGERY TO IDENTIFY RISK FACTORS FOR POST-OPERATIVE INFECTION I
06/23/2014 - 07/01/2017 (PI)
Icahn School of Medicine at Mount Sinai Crohns & Colitis Fdn

A STUDY TO ASSESS THE ASSOCIATION OF CLINICAL OUTCOME WITH SERUM DRUG CONCENTRATION LEVELS AND ANTI-DRUG ANTIBODY IN MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PATIENTS TREATED WITH ADALIMUMAB PROT
08/01/2011 - 07/31/2012 (PI)
Prometheus Laboratories, Inc.

PROCUREMENT OF BLOOD SAMPLES FROM IBD, GI CONTROLS AND HEALTHY VOLUN TEER SUBJECTS FOR USE IN THE
01/01/2011 - 12/31/2011 (PI)
Prometheus Laboratories, Inc.

C13006, A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, BLINDED, MULTICENTER STUDY FOR THE INDUCTION AND MAINTENANCE OF CLINICAL RESPONSE AND REMISSION BY VEDOLIZUMAB (MLN0002) IN PATIENTS WITH MODERA
04/01/2009 - 05/31/2011 (PI)
Millennium Pharmaceuticals, Inc.

C13007, A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, BLINDED, MULTICENTER STUDY FOR THE INDUCTION AND MAINTENANCE OF CLINICAL RESPONSE AND REMISSION BY VEDOLIZUAMB (MLN0002) IN PATIENTS WITH MODERA
04/01/2009 - 05/31/2011 (PI)
Millennium Pharmaceuticals, Inc.

A Phase IIIb Multi-Center, Double-Blind, Placebo-Controlled, Randomized Trial to Examine the Corticosteroid-Sparing Effects of Certolizumab Pegol in Patients with Moderate to Severe Crohn’s Disease (COSPAR I)
11/06/2006 - 11/05/2008 (PI)
UCB Pharma, Inc.

A Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severe Crohn’s Disease with Previous Exposure to Infliximab
12/08/2006 - 06/07/2007 (PI)
Abbott Laboratories

A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate for the Induction of Clinical Response in Patients with Crohn’s Disease
10/06/2005 - 10/05/2006 (PI)
Synta Pharmaceuticals Corporation

An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects with Irritable Bowel Syndrome
11/04/2004 - 07/19/2005 (PI)
GlaxoSmithKline, Inc.

Showing 10 of 14 results. Show All Results

Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)
06/23/2016 - 06/22/2019 (PI)
Beth Israel

Entyvio (velolizumab) long-term safety study
04/12/2016 - 03/31/2019 (PI)
Takeda Pharmaceuticals

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Ind…
03/31/2016 - 03/31/2019 (PI)
Celgene International II Sarl

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Invest to Invest…
10/03/2016 - 10/02/2018 (PI)
Celgene Corporation

An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Ac…
10/08/2015 - 09/30/2018 (PI)
Takeda Pharmaceuticals

A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Sev…
09/22/2016 - 09/21/2018 (PI)
Celgene International II Sarl

EH-5151- Evaluating the Nutritional Impact of Serum-Derived Bovine Immunoglobulin / Protein Isola…
07/25/2016 - 07/24/2018 (PI)
Entera Health, Inc.

Sample Collection Study to Evaluate DNA Markers in Subjects with Inflammatory Bowel Disease (IBD)…
12/22/2014 - 10/10/2017 (PI)
Exact Sciences

Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease:OCEANIA Study
12/12/2014 - 06/30/2017 (PI)
Exact Sciences

A Prospective, Randomized,Double Blinded, Placebo-Controlled Phase II Clinical Study of Trichuris…
05/01/2014 - 12/31/2015 (PI)
Duke University NIH-NIAID

Showing 10 of 15 results. Show All Results


Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Coukos J, Farraye FA. Update on Vaccinating the Patient With Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2018 Oct 06. PMID: 30293209.
     
  2. Reich J, Guo L, Groshek J, Weinberg J, Chen W, Martin C, Long MD, Farraye FA. Social Media Use and Preferences in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Sep 07.View Related Profiles. PMID: 30203036.
     
  3. Caldera F, Farraye FA, Kane S. The Who and Why of Herpes Zoster Vaccination in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018 Aug 25. PMID: 30153518.
     
  4. Tormey LK, Reich J, Chen YS, Singh A, Lipkin-Moore Z, Yu A, Weinberg J, Farraye FA, Paasche-Orlow MK. Limited Health Literacy Is Associated With Worse Patient-Reported Outcomes in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Jul 10.View Related Profiles. PMID: 29992302.
     
  5. Apte M, Reich J, Zahorian T, Farraye FA. Improving Vaccination Rates for IBD Patients Through the Use of Local Pharmacies. Inflamm Bowel Dis. 2018 Jun 09. PMID: 29893866.
     
  6. Szeto W, van der Bent A, Petty CR, Reich J, Farraye F, Fishman LN. Use of Social Media for Health-Related Tasks by Adolescents With Inflammatory Bowel Disease: A Step in the Pathway of Transition. Inflamm Bowel Dis. 2018 May 18; 24(6):1114-1122. PMID: 29788360.
     
  7. Limdi JK, Farraye FA. An Update on Surveillance in Ulcerative Colitis. Curr Gastroenterol Rep. 2018 Mar 07; 20(2):7. PMID: 29516293.
     
  8. Naidu H, Szeto W, Kissin E, Farraye FA. MAGIC Syndrome in a Patient With Crohn's Disease. Inflamm Bowel Dis. 2018 Feb 15; 24(3):664-665.View Related Profiles. PMID: 29462377.
     
  9. Pratt PK, David N, Weber HC, Little FF, Kourkoumpetis T, Patts GJ, Weinberg J, Farraye FA. Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy. Inflamm Bowel Dis. 2018 Jan 18; 24(2):380-386.View Related Profiles. PMID: 29361083.
     
  10. Limdi J, Farraye FA. Treatment of Inflammatory Bowel Disease with Biologics. Anti-integrin Agents in IBD: Efficacy and Risk of Complications. 2018; 283-301. View Publication
Showing 10 of 320 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 319 publications over 30 distinct years, with a maximum of 26 publications in 2010

YearPublications
19871
19883
19892
19901
19912
19921
19944
19964
19972
19983
19998
20005
20018
200211
200314
200415
200514
200614
20076
200818
200916
201026
201120
20129
201323
201417
201517
201624
201719
201812
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Colon Cancer
Colon Polyps
Crohn’s Disease
Dysplasia
Ileal Pouch Anal Anastomosis
Inflammatory Bowel Disease
Ulcerative Colitis
Vitamin D

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:


85 E. Concord St
Boston MA 02118
Google Map


Farraye's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department